XIAP Antibody

XIAP [human X-linked IAP, hILP (human IAP-like protein), MIHA, BIRC4) is a member of the family of inhibitor of apoptosis proteins (IAP). IAPs suppress mitochondria-dependent and independent apoptosis by binding to and inhibiting caspases through their BIR domains (reviewed in Liston et al, 2003; Wright and Duckett, 2005). Resistance towards apoptosis is a hallmark of cancer cells, and overexpression of IAPs can contribute to the development of cancer though inhibiting apoptosis. In addition to at least one BIR domain, some IAP members also have a RING-type finger motif at their carboxyl-terminal. The RING finger domain of several IAPs, including XIAP, have E3 ubiquitin ligase activity and target the degradation of Smac/DIABLO through ubiquitination (Morizane et al, 2005). Smac/DIABLO is a death inducer and functions by inhibiting IAP-caspase interactions, thereby promoting apoptosis. Degradation of cell death inducers like Smac/DIABLO is thought to be a conserved mechanism by which IAPs enhance their anti-apoptotic activity, thereby promoting cell survival. XIAP is highly characterized with respect to its structure and biochemical mechanisms and has received interest as a therapeutic target (reviewed in Schimmer, 2006). Since XIAP blocks a substantial portion of the apoptosis pathway and is associated with chemoresistance in cancer cells, inhibiting XIAP has been a focus for potential therapeutics. Approaches have included antisense oligonucleotides and small molecule inhibitors. Small molecules that that target the BIR2 and BIR3 domains of XIAP are considered particularly attractive. This is because the BIR domains inhibit caspase activity, and it is thought that removing the inhibition should increase the cell's ability to undergo apoptosis as well as decrease its potential for chemoresistance. Full-length human XIAP is a 497 amino acid protein and migrates at approx. 53 kDa on SDS-PAGE.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 2 applications: ICC/IF, WB.

Showing Publications 1 - 5 of 5.

Publications using NB100-56183	Applications	Species
Abdullah A, Ravanan P Kaempferol mitigates Endoplasmic Reticulum Stress Induced Cell Death by targeting caspase 3/7 Sci Rep. 2018-01-31 [PMID: 29391535] (ICC/IF, Human)	ICC/IF	Human
Su YT, Chen R, Wang H et al. Novel Targeting of Transcription and Metabolism in Glioblastoma. Clin. Cancer Res. 2017-12-18 [PMID: 29254993] (Mouse)		Mouse
Lee HI, Lee SW, Kim NG et al. Low-level light emitting diode (LED) therapy suppresses inflammasome-mediated brain damage in experimental ischemic stroke. J Biophotonics 2017-02-06 [PMID: 28164443] (WB, Mouse)	WB	Mouse
De Toni Enrico N, Ziesch Andreas, Rizzani Antonia et al. Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis. Oncotarget 2016-01-01 [PMID: 26843614] (WB, Human)	WB	Human
Lee J, Jiffar T, Kupferman ME. A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma. PLoS One. 2012-01-01 [PMID: 22276165]

Images	Ratings	Applications	Species	Date	Details
	5 reviewed by: PRAVEEN Dubey	WB	Rat	02/07/2022	View Summary Application Western Blot Sample Tested H9c2 whole cell lysate Species Rat Lot AR27A-083106C-05
	3 reviewed by: Verified Customer	IP	Human	04/20/2021	View Summary Application Immunoprecipitation Sample Tested AC16 Species Human Lot AR27A-083106C-05
Enlarge	5 reviewed by: Verified Customer	IP	Human	05/17/2019	View Summary Application Immunoprecipitation Sample Tested AC16 Species Human Lot AR27A-083106C-05

Array NB100-56183

• XIAP Antibodies
• XIAP Lysate
• XIAP Proteins
• XIAP Proteins and Enzymes
• XIAP ELISA